PedAM
Pediatric Disease Annotations & Medicines
| Disease | thrombocytopenia |
| Phenotype | C0019158|hepatitis |
| Sentences | 35 |
| PubMedID- 24010032 | Adinolfi, et al showed that hepatic fibrosis and altered production of thrombopoietin are central players in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis without splenomegaly (adinolfi et al. |
| PubMedID- 23857723 | Laboratory investigation revealed severe acute hepatitis with thrombocytopenia and coagulopathy. |
| PubMedID- 21188328 | Background and aims: thrombocytopenia in patients with chronic hepatitis c may be the result of several factors: bone marrow inhibition, the decrease of liver thrombopoietin production and an autoimmune mechanism. |
| PubMedID- 25728497 | Background: there are many potential causes of thrombocytopenia in patients with chronic hepatitis c (chc). |
| PubMedID- 21120192 | Suggested that thrombocytopenia in patients with hepatitis c infection may be due to a variety of non-immune and immune mechanisms [28]. |
| PubMedID- 24457056 | We report the case of a 51 - year – old caucasian female who developed a severe, reversible, immune thrombocytopenia associated with hepatitis c virus infection. |
| PubMedID- 20720351 | A case of severe thrombocytopenia in a patient with chronic hepatitis c caused by a single administration of pegylated interferon alpha 2a subsequent to 48 weeks of pegylated interferon alpha 2b plus ribavirin therapy. |
| PubMedID- 20460556 | Objective: to review the pharmacology and pharmacokinetics and evaluate the safety and efficacy of eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (itp) and thrombocytopenia associated with hepatitis c virus (hcv) cirrhosis. |
| PubMedID- 24047408 | The aim of this study was to determine whether abnormalities in the ipf were associated with thrombocytopenia in patients with hepatitis b virus-related chronic hepatitis (chb). |
| PubMedID- 24714308 | Another recent study concluded that anti-p antibodies contribute to thrombocytopenia associated with chronic hepatitis c virus infection [21]. |
| PubMedID- 24621321 | The ifn-α treatment is considered an immune-modulator and increases the risk for immune thrombocytopenia purpura in patients with hepatitis c [10], but the mechanism of ifn-induced autoimmune thrombocytopenia is unclear [10]. |
| PubMedID- 24696622 | Many recent studies have suggested a potential role for this novel agent in the treatment of thrombocytopenia associated with hepatitis-c infection. |
| PubMedID- 26417629 | Eltrombopag (revolade ) and thrombocytopenia in patients with hepatitis c. |
| PubMedID- 25764686 | thrombocytopenia in patients with chronic hepatitis c represents an obstacle for the initiation of antiviral treatment. |
| PubMedID- 25331767 | Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis c. |
| PubMedID- 26278293 | Association of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome with immune thrombocytopenia and graves' disease. |
| PubMedID- 23995112 | Eltrombopag is effective for the treatment of chronic hepatitis with thrombocytopenia, and portal vein thrombosis at this time has rarely been reported. |
| PubMedID- 25209590 | Severe thrombocytopenia in a patient with hepatitis c treated with eltrombopag from off-label drug use to on-label drug use: a case report. |
| PubMedID- 24304453 | thrombocytopenia in patients with chronic hepatitis c may represent an obstacle for the initiation of antiviral treatment. |
| PubMedID- 20308017 | Severe thrombocytopenia associated with acute autochthonous hepatitis e. |
| PubMedID- 23440139 | Thirteen pregnancies in ten patients diagnosed with autoimmune hepatitis, complicated by thrombocytopenia, were retrospectively analyzed. |
| PubMedID- 24653754 | In november 2012, the us food and drug administration (fda) approved eltrombopag (promacta), an oral thrombopoietin agonist, for treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of ifn-based therapy. |
| PubMedID- 20796207 | Epidemiology of thrombocytopenia in patients with chronic hepatitis c: more than meets the eye. |
| PubMedID- 25886818 | Eltrombopag received accelerated fda approval in the united states for the treatment of patients with chronic idiopathic thrombocytopenic purpura (itp) in 2008 and full approval in 2011. eltrombopag has been shown to effectively increase platelet counts and reduce thrombocytopenia-associated complications in patients with itp and hepatitis c [14-16]. |
| PubMedID- 20805953 | The increase in platelet counts after pse may also improve the svr rate in chronic hepatitis c patients with thrombocytopenia [111213]. |
| PubMedID- 23001404 | Improvement of thrombocytopenia in hepatitis c-related advanced fibrosis patients after sustained virological response. |
| PubMedID- 19689996 | thrombocytopenia in patients with chronic hepatitis c: a possible role of hcv on platelet progenitor cell maturation. |
| PubMedID- 24128106 | [eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis c: two case reports]. |
| PubMedID- 20796208 | Prevalence of thrombocytopenia among patients with chronic hepatitis c: a systematic review. |
| PubMedID- 22312391 | However, thrombocytopenia also occurs in patients with chronic hepatitis c without cirrhosis. |
| PubMedID- 26364898 | Recent studies have suggested a potential role of eltrombopag in the treatment of thrombocytopenia associated with hepatitis-c virus infection. |
| PubMedID- 20362495 | The mortality rate was 6/95 (6.3%) in patients who developed plasma leakage, 3/42 (7.1%) in patients who developed hepatitis, 5/93 (5.4%) in patients with severe thrombocytopenia, and 3/12 (25%) in the patients who demonstrated together all these severe manifestations. |
| PubMedID- 20731135 | This article represented a modern view on the problem of thrombocytopenia in patients with chronic hepatitis c, including it's role as an adverse event of antiviral therapy. |
| PubMedID- 24731162 | Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis c patients with thrombocytopenia and advanced fibrosis. |
| PubMedID- PMC4034027 | Recent reports suggest that certain polymorphisms in type i ifn signaling molecules are associated with ifn-induced neutropenia and thrombocytopenia in patients with chronic hepatitis c. ifnγ binds to a cell-surface receptor composed of two transmembrane polypeptides ifgr1 and ifgr2 resulting in activation of the janus kinases jak1 and jak2, phosphorylation of stat1, formation of stat1 homodimers, and activation of a specific set of genes that encode the effector molecules responsible for mediating its biological activity. |
Page: 1